- 英文名称
- Mitoxantrone
- 分子式
- C22H28N4O6
- 分子量
- 444.48
- 中文别名
- 1,4-二羟基-5,8-双[[2-[(2-羟乙基)氨基]乙基]氨基]-9,10-蒽醌; 米拖蒽醌; 米托恩醌; 1,4-二羟基-5,8-二[[2-[(2-羟基乙基)氨基]乙基]氨基]蒽-9,10-二酮; 1,4-二羟基-5,8-双((2-((2-羟基乙基)氨基)乙基)氨基)蒽-9,10-二酮; MITOXANTRONE; 1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedi; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione; Mitoxantrone (base and/or unspecified salts); MITOXANTRONUM; 1,4-Dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethylamino]-9,10-anthraquinone; MitoxantroneBase; PharmasubstanceEP4; [3H]-Mitoxantrone; dihydroxyanthraquinone; 1,4-dehydroxy-5,8-bis[[[2-(2-hydroxyethyl)amino]ethyl]amino]-9,19-antracenedion; MITOXANTRONUM AND THE INTERMEDIATES; mitoxanthrone; 1,4-bis-[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxy-9,10-anthracenedione; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis[[2-(2-hydroxy-ethylamino)ethyl]amino]anthraquinone; 1,4-Dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthraquinone; 1,4-Dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracen-9,10-dion; DHAQ; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
- 用途
- 蒽环类抗癌药，用于乳腺癌等癌症治疗；作为拓扑异构酶II抑制剂，也可抑制蛋白激酶C (PKC)，IC50值为8.5 μM；对人乳腺癌细胞系MDA-MB-231和MCF-7有细胞毒性，IC50分别为18 nM和196 nM；临床用于乳腺癌有突出疗效。
